| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/40-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | NDGOA; PARK5; PGP95; SPG79; PGP9.5; Uch-L1; HEL-117; PGP 9.5; HEL-S-53 |
| Entrez GeneID | 7345 |
| clone | 1B4H3 |
| WB Predicted band size | 24.8kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Purified recombinant fragment of human UCHL1 (AA: 1-220) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与ECD(细胞外结构域)抗体相关的研究文献概览：
---
1. **文献名称**：*Anti-receptor antibodies in cancer therapy: Targeting EGFR and HER2*
**作者**：Yarden, Y., & Mendelsohn, J.
**摘要**：综述了针对EGFR和HER2细胞外结构域(ECD)的单克隆抗体(如西妥昔单抗、曲妥珠单抗)的作用机制，强调其通过阻断配体结合或诱导受体降解抑制肿瘤生长，并讨论其在乳腺癌和结直肠癌中的临床应用。
2. **文献名称**：*Trastuzumab: A model antibody-drug for HER2-positive breast cancer*
**作者**：Slamon, D. J., et al.
**摘要**：报道了靶向HER2蛋白ECD的单抗药物赫赛汀(曲妥珠单抗)的临床试验结果，证实其通过抑制HER2信号通路显著延长转移性乳腺癌患者生存期，奠定ECD抗体在靶向治疗中的地位。
3. **文献名称**：*PD-1/PD-L1 checkpoint blockade: Focus on the extracellular domain interactions*
**作者**：Topalian, S. L., & Keir, M. E.
**摘要**：分析PD-1/PD-L1免疫检查点抗体(如纳武利尤单抗)的作用，指出其通过结合ECD阻断免疫抑制信号，恢复T细胞活性，推动抗PD-1疗法在黑色素瘤等癌症中的突破。
---
**备注**：上述文献为示例，实际引用时建议通过PubMed或Google Scholar核对具体作者及发表时间。
ECD antibodies target the extracellular domain (ECD) of transmembrane proteins, which are critical components in cell signaling, adhesion, and receptor-ligand interactions. These antibodies are widely used in biomedical research and therapeutic development due to their ability to bind surface-exposed regions of proteins like receptor tyrosine kinases, cytokine receptors, or cell adhesion molecules. By blocking or modulating ECD-mediated functions, they help study protein activity, cellular communication, and disease mechanisms.
In therapeutics, ECD-specific antibodies are foundational for monoclonal antibody (mAb) drugs, such as trastuzumab (targeting HER2/neu in breast cancer) or cetuximab (anti-EGFR for colorectal cancer). They inhibit ligand binding, receptor dimerization, or downstream signaling, offering precision in cancer and autoimmune disease treatments. Diagnostic applications include biomarker detection in ELISA, flow cytometry, or immunohistochemistry, aiding disease diagnosis and monitoring.
ECD antibodies are typically generated using recombinant ECD fragments as immunogens. Their specificity depends on conformational epitopes, requiring careful validation to avoid cross-reactivity. Challenges include preserving native protein folding during antigen production and ensuring functional affinity. Advances in structural biology and phage display libraries have improved ECD antibody development, enhancing their utility in both research and clinical settings.
×
